Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
In the latest session, Heron Therapeutics Inc (NASDAQ: HRTX) closed at $1.72 down -3.37% from its previous closing price of $1.78. In other words, the price has decreased by -$3.37 from its previous closing price. On the day, 1.04 million shares were traded.
Ratios:
For a deeper understanding of Heron Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.74 and its Current Ratio is at 2.28.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Rodman & Renshaw on June 13, 2024, initiated with a Buy rating and assigned the stock a target price of $7.
On April 23, 2024, CapitalOne started tracking the stock assigning a Overweight rating and target price of $6.
Needham reiterated its Buy rating for the stock on March 13, 2024, while the target price for the stock was revised from $4 to $5.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 1.90.
Stock Price History:
Over the past 52 weeks, HRTX has reached a high of $3.93, while it has fallen to a 52-week low of $1.04. The 50-Day Moving Average of the stock is 3.68%, while the 200-Day Moving Average is calculated to be -22.37%.
Shares Statistics:
A total of 151.70M shares are outstanding, with a floating share count of 150.69M. Insiders hold about 0.92% of the company’s shares, while institutions hold 75.77% stake in the company.
Earnings Estimates
The market rating of Heron Therapeutics Inc (HRTX) is currently shaped by the ongoing analysis conducted by 2.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.02, with high estimates of -$0.02 and low estimates of -$0.02.
Analysts are recommending an EPS of between -$0.1 and -$0.14 for the fiscal current year, implying an average EPS of -$0.12. EPS for the following year is -$0.03, with 2.0 analysts recommending between $0.0 and -$0.05.
Revenue Estimates
A total of 3 analysts believe the company’s revenue will be $37.37M this quarter.It ranges from a high estimate of $38.2M to a low estimate of $36.5M. As of the current estimate, Heron Therapeutics Inc’s year-ago sales were $34.23MFor the next quarter, 3 analysts are estimating revenue of $34.25M. There is a high estimate of $34.25M for the next quarter, whereas the lowest estimate is $34.25M.
A total of 3 analysts have provided revenue estimates for HRTX’s current fiscal year. The highest revenue estimate was $141.7M, while the lowest revenue estimate was $140M, resulting in an average revenue estimate of $140.87M. In the same quarter a year ago, actual revenue was $127.04MBased on 3 analysts’ estimates, the company’s revenue will be $160.63M in the next fiscal year. The high estimate is $164.9M and the low estimate is $155M.
